— Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected.
— Net loss amounted to $5.7 million compared to $6.6 million last year.
— R&D expenses were $5.3 million compared to $5.7 million in the year-ago quarter.
— General and administrative expenses were $2.2 million compared to $1.7 million last year.
— At quarter-end, the company had cash, cash equivalents and short-term investments of $288.1 million.
— VKTX shares gained 0.15% following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Infographic: Nvidia (NVDA) Q4 revenue up 61%; earnings beat
Nvidia Corporation (NASDAQ: NVDA) Wednesday said its fourth-quarter revenues and profit increased in double-digits amid elevated demand. The results also topped the Street view, driving the stock higher during the
Nutanix (NTNX) Earnings: 2Q21 Key Numbers
Nutanix (NASDAQ: NTNX) reported second quarter 2021 earnings results today. Total revenue remained flat at $346.4 million compared to the same period a year ago. GAAP net loss was $287.3
Macy’s (M) expects digital channels to generate approx. $10 billion in sales by 2023
Shares of Macy’s Inc. (NYSE: M) were down 2.7% in morning trade on Wednesday. The stock has gained 37% since the beginning of the year. A day ago, the retailer
